The Clinical Effects of Type 2 Diabetes Patient Management Using Digital Healthcare Technology: A Systematic Review and Meta-Analysis.
Ji-Eun KimTae-Shin ParkKwang Joon KimPublished in: Healthcare (Basel, Switzerland) (2022)
The disease control rate is very low (at less than 30%) for diabetes. The use of digital healthcare technology is increasing recently for continuous management in daily life. In this study, a meta-analysis was conducted to evaluate the clinical effects of digital healthcare technology for patients with type 2 diabetes management. For a review of the literature, databases such as PubMed, Embase, and Cochrane Library were searched using Medical Subject Heading (MeSH) terms published up to 9 August 2021. As a result, 2354 articles were identified, and 12 randomized controlled trial articles were finally included. Digital healthcare technology combined management for type 2 diabetes significantly decreased HbA1c ( p < 0.00001, standardized mean difference (SMD) = -0.49) and marginally decreased triglyceride, compared with usual care ( p = 0.06, SMD = -0.18). However, it did not significantly affect BMI ( p = 0.20, SMD = -0.47), total cholesterol ( p = 0.13, SMD = -0.19), HLD-C ( p = 0.89, SMD = -0.01), LDL-C ( p = 0.95, SMD = -0.01), systolic BP ( p = 0.83, SMD = 0.03), or diastolic BP ( p = 0.23, SMD = 0.65), compared with usual care. These results indicate that digital healthcare technology can improve HbA1c and triglyceride levels of type 2 diabetes patients. Further well-designed randomized controlled clinical trials are needed to confirm the clinical effect of digital healthcare technology.
Keyphrases
- healthcare
- type diabetes
- randomized controlled trial
- clinical trial
- blood pressure
- glycemic control
- left ventricular
- ejection fraction
- body mass index
- study protocol
- palliative care
- end stage renal disease
- open label
- quality improvement
- machine learning
- systematic review
- low density lipoprotein
- double blind
- adipose tissue
- insulin resistance
- metabolic syndrome
- peritoneal dialysis
- weight loss
- phase ii
- placebo controlled